International Strategies for Tropical Disease Treatments: Experiences with praziquantel, edited by Michael R. Reich, with contributions from: Michael R. Reich, Ramesh Govindaraj, Karin Dumbaugh, Bong-min Yang, Agnes Brinkmann, and Sameh El-Saharty.
This report identifies national and international policies that have facilitated or hindered the availability of praziquantel, the drug of choice for all forms of schistosomiasis occurring in humans. The report gives particular attention to questions of access for people in the world's poorest countries in Africa where schistosomiasis is endemic. The analysis of praziquantel illustrates more general problems in the design of national and international policies for tropical disease products, and suggests strategies for future research and action. The report’s seven chapters are: Chapter 1: Policies for praziquantel; Chapter 2: Bayer & E. Merck: Discovery and development of praziquantel; Chapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea; Chapter 4: Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation; Chapter 5: The international supply of praziquantel; Chapter 6: Demand for praziquantel and national distribution; and Chapter 7: Prices and production costs for praziquantel.
This research project was carried out through the Takemi Program in International Health, at the Harvard School of Public Health (665 Huntington Avenue, Boston, MA, USA 02115), with the financial support of the Edna McConnell Clark Foundation.